782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797386987601133568 |
|---|---|
| author | Paolo A Ascierto Georgina V Long Michael Chisamore Paola Queirolo Adnan Khattak Anders Jespersen Daniela Kleine-Kohlbrecher Nadia Viborg Mads Lausen Stine F Thorsen Thomas Trolle |
| author_facet | Paolo A Ascierto Georgina V Long Michael Chisamore Paola Queirolo Adnan Khattak Anders Jespersen Daniela Kleine-Kohlbrecher Nadia Viborg Mads Lausen Stine F Thorsen Thomas Trolle |
| author_sort | Paolo A Ascierto |
| collection | DOAJ |
| first_indexed | 2024-03-08T22:17:22Z |
| format | Article |
| id | doaj.art-71b5b7000a494548b6f07ae48b302987 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-08T22:17:22Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-71b5b7000a494548b6f07ae48b3029872023-12-18T20:30:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 210.1136/jitc-2023-SITC2023.0782-H782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial updatePaolo A Ascierto0Georgina V Long1Michael Chisamore2Paola Queirolo3Adnan Khattak4Anders Jespersen5Daniela Kleine-Kohlbrecher6Nadia Viborg7Mads Lausen8Stine F Thorsen9Thomas Trolle102Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy7Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia4Merck and Co., Inc., Rahway, NJ, USA3IEO European Institute of Oncology IRCCS, Milan, Italy1Hollywood Private Hospital and Edith Cowan University, Perth, Western Australia, Australia6Evaxion Biotech, Hoersholm, Zealand, Denmark5Evaxion Biotech, Horsholm, Denmark6Evaxion Biotech, Hoersholm, Zealand, Denmark6Evaxion Biotech, Hoersholm, Zealand, Denmark5Evaxion Biotech, Horsholm, Denmark6Evaxion Biotech, Hoersholm, Zealand, Denmark |
| spellingShingle | Paolo A Ascierto Georgina V Long Michael Chisamore Paola Queirolo Adnan Khattak Anders Jespersen Daniela Kleine-Kohlbrecher Nadia Viborg Mads Lausen Stine F Thorsen Thomas Trolle 782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update Journal for ImmunoTherapy of Cancer |
| title | 782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update |
| title_full | 782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update |
| title_fullStr | 782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update |
| title_full_unstemmed | 782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update |
| title_short | 782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update |
| title_sort | 782 h effects of an ai generated personalized neopeptide based immunotherapy evx 01 in combination with pembrolizumab in patients with metastatic melanoma a clinical trial update |
| work_keys_str_mv | AT paoloaascierto 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT georginavlong 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT michaelchisamore 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT paolaqueirolo 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT adnankhattak 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT andersjespersen 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT danielakleinekohlbrecher 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT nadiaviborg 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT madslausen 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT stinefthorsen 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate AT thomastrolle 782heffectsofanaigeneratedpersonalizedneopeptidebasedimmunotherapyevx01incombinationwithpembrolizumabinpatientswithmetastaticmelanomaaclinicaltrialupdate |